Relatlimab（BMS-986016）是一种全人源单克隆抗体，通过使用重组LAG-3蛋白免疫转基因人源化小鼠制备而成，能够以高亲和力阻断LAG-3与MHC II的相互作用，同时有效抑制LAG-3与FGL1的结合。

Purity:SDS-PAGE

Anti-LAG3 / CD223 Reference Antibody (relatlimab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

Purity:SEC-HPLC

The purity of Anti-LAG3 / CD223 Reference Antibody (relatlimab) is 100%, determined by SEC-HPLC.

Bioactivity:ELISA

Immobilized human LAG3 His at 2 ug/mL can bind Anti-LAG3 / CD223 Reference Antibody (relatlimab), EC50=0.02812 ug/mL.

Bioactivity:FACS

Human LAG3 CHO cells were stained with Anti-LAG3 / CD223 Reference Antibody (relatlimab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC50=0.5464 ug/mL.

Research in vivo

Relatlimab inhibited the tumor growth of MC38 on Human LAG3 mice. The result showed significant anti-tumor effects, with an tumor inhibition rate (TGI) of 53.8% at 10 mpk at D28.

-25~-15℃保存，有效期1年。